Drug facts
BrandVerzenio (Abemaciclib)
No generic abemaciclib is approved; the latest Verzenio patent or exclusivity in the Orange Book runs to 09/28/2031. 1 staged generic application passed FDA review and waits on patents or exclusivity.
Verzenio was first approved by the FDA on 09/28/2017 under NDA 208716; the application holder is Eli Lilly and Co.
Holder Eli Lilly and CoApplication NDA 208716Approved 09/28/2017
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
1,793days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved09/28/2017
Last patent09/28/2031
201820212024202720302033
- Latest patent
- 09/28/2031Verzenio Orange Book
02Competition
- Generics
- No generic approved Orange Book
- Staged generics
- 1 passed FDA review, awaiting market entry FDA
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Verzenio profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Eli Lilly and Co Orange Book
- Application
- NDA 208716 Orange Book
- First approved
- 09/28/2017 Orange Book
- Dosage forms
- tablet
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.